K984634

510(K) SUMMARY FOR THE 3D-ANGIO SOFTWARE OPTION

Submitted by:

Siemens Medical Systems, Inc. 186 Wood Avenue South Iselin, NJ 08830

December 28, 1998

This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.

1. Contact Person:

Ms. Malgorzata Stanek

Phone: (732) 321-3950 Fax: (732) 321-4841

2. Device Name and Classification:

Trade Name:

3D-Angio

Classification Name:

Accessory to Angiographic X-Ray System

Classification Panel:

Radiology

CFR Section:

21 CFR §892.1600

Device Class:

Class I.I.

Product Code:

90JAA

3. Substantial Equivalence:

The 3D-Angio software option is designed for three-dimensional evaluation of data acquired with a standard angiographic C-arm devices. The package is substantially equivalent to the following device:

Siemens Device Name	FDA Clearance Number	FDA Clearance Date
GE Advantage 3D XR	K974715	7/6/98

4. Device Description:

The 3D-Angio package is a x-ray imaging software option which allows the reconstruction of two-dimensional images acquired with a standard angiographic C-arm device into a three-dimensional image format.

5. Intended Use of the Device:

The resulting images of the 3D-Angio package are intended to assist the physician in diagnosis and treatment of vessel malformations (i.e. aneurysms, AVMs, stenoses), particularly neuro-angiographic cases.

6. Summary of Technological Characteristics of the Devices Compared to the Predicate:

Both the Siemens 3D-Angio software option and GE Advantage 3D XR allow construction of a three-dimensional model from images acquired during rotational angiography.

Kathleen Rutherford

Manager, Regulatory Submissions Siemens Medical Systems, Inc.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 1 2 1999

Malgorzata Stanek
Technical Specialist
Siemens Medical Systems, Inc.
186 Wood Ave. South
Iselin, NJ 08830

Re: K984634

3D-Angio (3D Angiographic Accessory)

Dated: December 28, 1998 Received: December 30, 1998

Regulatory class: II

21 CFR 892.1600/Procode: 90 JAA

Dear Ms. Stanek:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours

CAPT Daniel G. Schultz, M.D.

Acting Director, Division of Reproductive,

Abdominal, Ear, Nose and Throat,

and Radiological Devices Office of Device Evaluation Center for Devices and

Radiological Health

INDICATIONS FOR USE

510(k) Number (if known): <u>K984634</u>
Device Name: 3D-Angio
Indications For Use:
The 3D-Angio package is a x-ray imaging software option which allows the reconstruction of two-dimensional images acquired with a standard angiographic C-arm device into a three-dimensional image format.
The 3D-Angio package is intended to assist the physician in diagnosis and treatment of vessel malformations (i.e. aneurysms, AVMs, stenoses), particularly neuro-angiographic cases.
(Please do not write below this line - continue on another page if needed)
Concurrence of the CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices 510(k) Number <u>K984634</u>
Prescription Use OR Over-The-Counter Use (Per 21 CFR 801.109)

Pg. 68

510(k) for 3D-Angio